Irving-based Biote Corp., which offers solutions in preventive healthcare through the delivery of personalized hormone therapy, has appointed Mary J. Puncochar as chief commercial officer.
Puncochar will lead Biote’s commercial initiatives to expand its presence in the growing market for hormone replacement therapy.
“Mary is a proven and dynamic leader who has substantial experience in managing teams, driving profitable growth and commercializing products aimed at enhancing patient health and wellness,” CEO Terry Weber said in a statement. “I believe Mary will be a tremendous asset to Biote as we expand our geographic presence, build our relationships with healthcare providers and continue to strengthen the Biote brand.”
Puncochar brings more than 30 years’ experience in sales, tech-enabled marketing and management roles at leading healthcare, pharmaceutical, and medical device companies.
Before Biote, she was head of the U.S. region at Ascensia Diabetes Care, a global diabetes care company, where she achieved commercial success through the development and launch of innovative solutions and precision tools aimed at helping consumers more effectively manage their health.
“It’s an honor to join Biote and advance the company’s mission of connecting healthcare providers and consumers to preventive treatments that are transforming healthy aging,” Puncochar said. “I’m excited to join Biote’s talented team during this time of growth and am eager to drive adoption of the Biote Method.”
Puncochar started her career as a healthcare provider at the University of Minnesota and has also held positions of increasing responsibility at companies including Bayer, Columbia Park Medical Group, InHome Services, and Honeywell.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.